Prediction of outcomes after radiotherapy for the patients with advanced cervical cancer using the molecular technique

2016 Fiscal Year Final Research Report

• Project/Area Number: 25293266
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Partial Multi-year Fund
• Section: 一般
• Research Field: Radiation science
• Research Institution: Kansai Medical University
• Principal Investigator: HARIMA Yoko 関西医科大学, 医学部, 非常勤講師 (80140276)
• Co-Investigator(Renkei-kenkyūsha): NAKANO Takashi 群馬大学, 大学院医学系研究科, 教授 (20211427) ; OHNO Tatsuya 群馬大学, 重粒子線医学推進機構, 教授 (10344061) ; TOITA Takafumi 琉球大学, 医学部, 客員教授 (30237036) ; IKUSHIMA Hitoshi 徳島大学, 大学院医歯薬学研究部, 教授 (90202861) ; TOKUMARU Sunao 兵庫県立粒子線医療センター, 診療部, 副院長 (90304899) ; KANEYASU Yuko 広島大学, 医歯(薬)学総合研究科, 非常勤医師 (90204586) ; IKEDA Koshi 関西医科大学, 医学部, 講師 (80288802) ; UTSUNOMIYA Keita 関西医科大学, 医学部, 准教授 (20193914)
• Project Period (FY): 2013-04-01 – 2017-03-31
• Keywords: 放射線 / 子宮頸癌 / 予後予測 / バイオマーカー

Outline of Final Research Achievements

We previously identified serum apolipoprotein C-II (ApoC-II) before radiation therapy as a prognostic biomarker for clinical outcomes in patients with locally advanced cervical cancer (Int J Radiat Oncol Biol Phys, 87: 1155-1161, 2013).
In 2012, to further assess ApoC-II as a prognostic biomarker in this population, we started a prospective study in cooperation with gynecology tumor group in Japanese Radiation Oncology Study Group (JROSG). One hundred and forty-eight patients in 13 institutions were enrolled. Preliminary results of the study were presented at the 29th Annual Meeting of Japanese Society for Radiation Oncology. Lower serum levels of ApoC-II (<28.5 μg/mL) were significantly associated with shorter pelvic progression-free survival (P=.019). The final results of this study are being analyzed and will be published soon.

Free Research Field

放射線腫瘍学